Home   About this service   Get the news  
+32 2 743 34 03

 Belgium  Other Countries
Page : 1 - 2 - ... 7 - 8 - 9 - 10 - 11 - 12 - 13 - ...
UCB [BE0003739530/UCB]   
[23/04/2021]

UCB : UCB Media Room: UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021

https://mb.cision.com/Public/18595/logo/86a99b25f755738d_org.jpg UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021 Brussels, Belgium =E2=80=93 April 23, 2021, 16:15 CEST =E2=80=93 UCB, a glo= bal biopharmaceutical company, today announced that 12 abstracts on bimekiz= umab, an investigational IL17A and IL17F inhibitor, in the treatment of a= dults with moderate to severe... See more
 
UCB [BE0003739530/UCB]   
[23/04/2021]

UCB : UCB Media Room: bimekizumab in the New England Journal of Medicine

https://mb.cision.com/Public/18595/logo/86a99b25f755738d_org.jpg The New England Journal of Medicine Publishes Results from Two Bimekizum= ab Phase 3 Studies in Moderate to Severe Plaque Psoriasis =C2=B7 Today, two manuscripts published back to back detail the full result= s from the BE RADIANT and BE SURE studies, comparing the efficacy and safet= y of bimekizumab to secukinumab and... See more
 
UCB [BE0003739530/UCB]   
[22/04/2021]

UCB : UCB Media Room: zilucoplan in immune-mediated necrotizing myopathy (IMNM)

https://mb.cision.com/Public/18595/logo/86a99b25f755738d_org.jpg UCB=E2=80=99s zilucoplan shows no relevant effect in immunemediated nec= rotizing myopathy IMNM =C2=B7 In phase 2, zilucoplan did not show a meaningful effect in immuneme= diated necrotizing myopathy IMNM=C2=A0 =C2=B7 No unexpected safety findings and no relevant safety differences bet= ween zilucoplan and placebo were... See more
 
UCB [BE0003739530/UCB]   
[20/04/2021]

UCB : UCB Media Room: Acquisitions and Disposals of own shares

https://mb.cision.com/Public/18595/logo/86a99b25f755738d_org.jpg Acquisitions of own shares and Disposals of own shares Brussels Belgium, 20 April 2021 =E2=80=93 20:00 CEST =E2=80=93 regulate= d information Acquisitions of own shares In accordance with article 8:4 of the Royal Decree of 29 April 2019 executi= ng the Belgian Code on Companies and Associations, UCB SA/NV... See more
 
INVIBES ADVERTSING [BE0974299316/ALINV]   
[20/04/2021]

INVIBES ADVERTSING : Invibes Advertising announces a successfully capital increase through private placement of EUR 5m.

p align=centerstrongInvibes Advertising announces a successfully capital increase through private placement of €5m/strong/p ul listrongPrivate placement carried out at €9.50 with Generis Capital Partners, NextStage AM and other private investors the “Investors” for €5m;/strong/li listrongLimitation, if not potential outright cancellation, of dilution...